USC.edu
Are You a Patient?

Deepa Bhojwani, MBBS, DCH

Professor of Pediatrics (Clinical Scholar)

Image of Deepa Bhojwani, MBBS, DCH
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Publications

  • Characterization of PAX5 intragenic tandem multiplication in pediatric B-lymphoblastic leukemia by optical genome mapping. Blood Adv. 2022 06 14; 6(11):3343-3346.. View in PubMed
  • Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood. 2022 05 26; 139(21):3159-3165.. View in PubMed
  • Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun; 150:113000.. View in PubMed
  • Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 05; 97(5):613-622.. View in PubMed
  • Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children’s Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967.. View in PubMed
  • Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program. 2021 12 10; 2021(1):376-383.. View in PubMed
  • Acute myeloid leukemia with t(X;6)9p11;q23);MYB-GATA1 and female sex: GATA1 insufficiency may be insufficient for pathogenesis. Cancer Genet. 2022 01; 260.. View in PubMed
  • Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. Front Oncol. 2021; 11:766888.. View in PubMed
  • In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia. Exp Ther Med. 2022 Jan; 23(1):47.. View in PubMed
  • Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2022 03 20; 40(9):932-944.. View in PubMed

Similar People